



Simplifying Progress

This is
Sartorius Stedim Biotech
2026

SARTORIUS

Our purpose: Better health for more people

Mission

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.



Sartorius Stedim Biotech in 2025 numbers



~€3.0bn
Sales revenue




30.8%
Profit margin¹



10,200+
Employees



~€390mn
Investments



50+
Locations worldwide

¹ Underlying EBITDA margin

More than 10,200 employees united by strong values

Sustainability
Growing profitably and acting responsibly towards all stakeholders



Openness
Driving change and progress internally and externally



Enjoyment
Working in an energetic and rewarding environment



96 Nationalities

54% Younger than 40 years


40% Women

74% Management positions filled internally

What are biopharmaceuticals?

Chemical drugs

Aspirin
(C₉H₈O₄)



Small, simple molecules




Obtained via chemical synthesis



Administered in various ways

Biopharmaceuticals

Monoclonal antibody



Large molecules, cells or viruses



Produced with living cells in cell culture processes



Administered mainly intravenously


Advantages of biopharmaceuticals

- Target only diseased cells
- Fewer side effects
- Allow first-time or improved treatment of illnesses, e.g. cancer, multiple sclerosis, rheumatism



The promises of biologics: From established to new concepts

Breakthroughs at an ever-increasing pace and new forms of treatment offer hope for patients



Many biotech medications are highly effective, but very expensive

Rheumatism

Monoclonal antibodies



~€12,000

Annual cost of treatment in GER

Blood cancer

CAR-T cell therapy



~€240,000

Cost per treatment in Europe

Leukodystrophy

Gene therapy




~\$4.25mn

Cost per treatment in the USA

The manufacture of biologics is complex



Providing technologies to increase productivity in bioprocessing

 Our ambition
More efficient bioprocessing

 Our solutions
Technologies for all phases of drug manufacturing




- Set up safe and flexible processes
- Increase resource and material efficiency
- Reduce investments
- Enhance product yield



Media & reagents



Bioreactors & fermenters



Chromatography



Filtration




Fluid management




Data analysis

Offering integrated end-to-end manufacturing solutions


Upstream
Production of the desired drug



Downstream
Isolation and filling of the desired drug




Pioneering the industry: New platform supports transition from batch to continuous bioprocesses




A black rectangular box with four white icons and text blocks. Top-left: 'Lower production costs' with a stack of coins and a downward arrow. Top-right: 'Higher productivity' with a gear and an upward arrow. Bottom-left: 'Fewer CO₂-emissions' with a cloud and a downward arrow labeled 'CO₂'. Bottom-right: 'Shorter time-to-market' with a stopwatch icon.

Pionic®

Cooperation with **sanofi**



Cell and gene therapies: New modalities, new challenges



Next generation biopharmaceuticals

Viral Vectors	mRNA	Stem Cells
Exosomes	DNA	New Vaccines

Innovative treatments for patients

8,700+	Candidates in development ¹
~100	Approved therapies worldwide

¹ Global Data, January 2026, CGT = Cell & Gene Therapies




Enabling CGT: High need for innovation

- + Robustness of production process
- + Yields, productivity, cost-per-dose
- + Time-to-market
- + Regulation under development
- + Manufacturing close to patients



Extensive technology platform for cell and gene therapy applications



Ongoing investment in innovation, growth and resilience



Songdo, South Korea
Sterile consumables, labs

Göttingen, Germany
Filter


Nottingham, UK
Cell culture components

Freiburg, Germany
Cell culture components


Bielefeld, Germany
Media

2025
€390mn
Investment

13.3 %
Investment ratio



Strong financial track record; profitable growth



Sales CAGR for continued operations; EBITDA margin excluding extraordinary items

Ambitious mid-term climate agenda in line with Paris Climate Agreement

2030 mid-term ambitions

Scope 1 & 2

42%

Reduction of GHG emissions compared to 2022



Use of renewable energy & electrification of infrastructure

Scope 3

51.6%

Reduction of GHG emissions relative to value added¹ compared to 2022



Decarbonization of suppliers, eco-design, logistics, building construction



2045 long-term ambition

Net-zero emissions



¹ EBITDA plus personnel costs

Simplifying Progress

Sartorius Stedim Biotech
Zone Industrielle les Paluds
510 avenue de Jouques
13400 Aubagne
France

SARTORIUS